Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study

Li-Chung Huang1,2,3, Shih-Hsien Lin4,5, Huai-Hsuan Tseng4,5, Kao Chin Chen4, Muhammad Abdullah6 and Yen Kuang Yang4,5,7

1Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan; 2Department of Psychiatry, Chia-Yi Branch, Taichung Veteran General Hospital, Chia-Yi, Taiwan; 3Department of Counseling, National Chia-Yi University, Chia-Yi, Taiwan; 4Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 5Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 6Taiwan International Graduate Program in Interdisciplinary Neuroscience, National Cheng Kung University and Academia Sinica, Taipei, Taiwan and 7Department of Psychiatry, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan

Abstract

Background. Treatment-resistant schizophrenia (TRS) and non-TRS may be associated with different dopaminergic and glutamatergic regulations. The concept of dysregulated glutamatergic concentrations in specific brain regions remains controversial. Herein, we aimed to assess (i) the distribution of the glutamatergic concentration in the brain, (ii) the association between working memory (WM) differences in TRS and non-TRS patients, and (iii) whether an alteration in the glutamate (Glu) level is associated with WM.

Methods. The participants included 38 TRS patients, 35 non-TRS patients, and 19 healthy controls (HCs), all of whom underwent 1.5-Tesla proton magnetic resonance spectroscopy of anterior cingulate cortex (ACC) and medial prefrontal cortex (MPFC). The ratios of glutamatergic neurometabolites to N-acetylaspartate + N-acetyl aspartylglutamate (NAAXs) were calculated. Cognitive function was assessed using the Wechsler Adult Intelligence Scales, 4th Edition, which included the working memory index (WMI).

Result. The TRS patients had a higher glutamate + glutamine (Glx)/NAAX ratio compared to the non-TRS patients and HCs in the ACC, but this was not significantly different in the MPFC. WM was negatively correlated with Glx/NAAX in the ACC among the non-TRS patients, but not in the TRS patients or HCs.

Conclusions. Our findings were consistent with most studies indicating that the glutamatergic concentration in the ACC plays important roles in the classification of TRS and cognition. Our results may provide potential evidence for predictors and treatment response biomarkers in TRS patients. Further research is needed to probe the value using the relationship between Glu and WM as a potential prognostic predictor of schizophrenia.

Introduction

Schizophrenia, a neurodegenerative disorder with functional decline, may become a burden on patients and their families, and results in increased medical costs and negative effects on public health (Charlson et al., 2018; McCutcheon, Marques, & Howes, 2020). Currently, one-third of patients with schizophrenia are defined as having treatment-resistant schizophrenia (TRS), and exhibit a poor medication response with current antipsychotic agents, including first-and second-generation antipsychotics, clozapine (as the last-line medication), and integrated antipsychotics with high dosages and appropriate treatment durations (Howes et al., 2017a). Based on the concepts of maternal infection, inflammation, genetic expression, stress on endocrine systems, and neurotransmitters, and in particular the dopaminergic and glutamatergic hypotheses, the mechanisms of schizophrenia and TRS are mutative (Howes, McCutcheon, Owen, & Murray, 2017b; Huang, Lin, Tseng, Chen, & Yang, 2020; Nucifora, Woznica, Lee, Cascella, & Sawa, 2019). Considering that first- and second-generation antipsychotic agents are mostly based on the dopaminergic hypothesis, glutamate neurometabolites might play another critical role in major psychiatric disorders, especially in schizophrenia and TRS (Li, Yang, & Lin, 2019). Some studies have indicated that dopamine activity in the striatum and imbalances in glutamatergic neurometabolites in all cortical regions of the brain may cause psychotic symptoms and functional decline (Howes, McCutcheon, & Stone, 2015; Huang et al., 2020; Lin, Hashimoto, & Lane, 2019a). Some efficacious medications based on the glutamatergic hypothesis, including N-methyl-D-aspartate (NMDA) receptor agonists, glycine...
transporter inhibitors, \( \alpha \)-amino acid oxidase inhibitors, and anticonvulsants, have resulted in a good treatment response in patients with psychiatric disorders (Lin, Chen, & Lane, 2020a; Lin & Lane, 2019; Lin, Yang, Chen, Wang, & Lane, 2020b; Lin, Yang, & Lane, 2019b; Tsang, Chang, Chang, & Lane, 2019). Therefore, the integrated glutamatergic and dopaminergic hypotheses is considered one of the explanations for schizophrenia classification. The clinical implications of the integrated hypothesis may enable the additional use of glutamate as a predictor (Corcoran et al., 2020; Lin et al., 2019a; Tarumi et al., 2020) and biomarker of treatment response and cognitive function (Corcoran et al., 2020; Hutcheson et al., 2012; Kraguljac et al., 2018; Shah et al., 2020; Tarumi et al., 2020), respectively.

In \( \textit{in vivo} \) studies, extracellular levels of glutamate neurometabolites, such as in the serum and cerebrospinal fluid, and intracerebrally in various brain regions, have been measured (Borisova et al., 2018; Lin et al., 2019a). Several studies have shown that proton magnetic resonance spectroscopy (\( ^{1} \text{H-MRS} \)) is an effective method by which to estimate glutamate (Glu) and glutamine (Gln) concentrations in specific brain regions of patients with schizophrenia (Hutcheson et al., 2012; Shah et al., 2020; Tarumi et al., 2020; Wijtenburg et al., 2017). Unlike the dopaminergic system, which focuses on the substantia nigra and striatum (Huang et al., 2020; Tanaka, 2006), specific regions of interest (ROIs) for the measurement of glutamate activities in schizophrenia, including cortical areas such as the anterior cingulate cortex (ACC), dorsal lateral prefrontal cortex (DLPFC), hippocampus, thalamus, caudate, and medial prefrontal cortex (MPFC), are still being investigated (Conus et al., 2018; Corcoran et al., 2020; de la Fuente-Sandoval et al., 2018; Singh et al., 2018; Tarumi et al., 2020).

The ACC is located in a transport area of the brain, which connects the limbic system, controls emotion, and integrates the neuronal circuitry of affect, attention, dopaminergic activities and the prefrontal cortex, known to be associated with cognitive function (Stevens, Hurley, & Taber, 2011). In structural concepts, such as Brodmann mapping or Vgot’s system (Stevens et al., 2011), the ACC is divided into different subgroups anatomically, which may include the following: (1) the caudal or dorsal ACC or middle cingulate cortex; and (2) the ventral ACC, including pregenual regions and subgenual regions, which are considered part of the MPFC. Different brain regions present different patterns of glutamatergic neurometabolites in schizophrenia (Nakahara et al., 2021; Thomas, Bozaoglu, Rossell, & Gurvich, 2017). Most studies suggest that the ACC might be an important ROI, but the distribution of glutamate levels in this region may not be associated with the positive and negative syndrome scale (PANSS) severity, which is compatible with other evidence (Reddy-Thooktur, Kraguljac, & Lahti, 2020; Tarumi et al., 2020). Two of the most famous brain regions, the ACC and MPFC, have presented controversial results in terms of the glutamatergic levels in schizophrenia patients (Nakahara et al., 2021; Smucny, Carter, & Maddock, 2021; Thomas et al., 2017), though these two regions are anatomically adjacent in the brain. To date, the findings remain controversial, perhaps due to several important differences between studies. Specific brain regions in which the glutamate activity has been measured do not correspond with specific subgroups of schizophrenia, such as TRS (Shah et al., 2020; Tarumi et al., 2020), treatment-responsive or non-treatment-resistant schizophrenia (non-TRS) (Shah et al., 2020; Wijtenburg et al., 2017), first-episode psychosis (de la Fuente-Sandoval et al., 2018), ultra-TRS (Shah et al., 2020), and acute or chronic states (Reddy-Thooktur et al., 2020; Thomas et al., 2017; Wijtenburg et al., 2017). These studies do not consistently present a clear scheme of the glutamate hypothesis regarding neurometabolite fluctuations. In addition, the most appropriate scale of measurement, i.e. concentration or ratio, remains unclear.

Cognitive function decline is not only a measure of treatment outcome with medication or non-medication rehabilitation for schizophrenia, but also reduces a patient’s quality of life, which may lead to a burden on their family (Fernandes, Cajião, Lopes, Jerónimo, & Barahona-Corrêa, 2018; Forbes, Carrick, McIntosh, & Lawrie, 2009; Guo, Ragland, & Carter, 2019). Cognitive deficits in schizophrenia have been categorized in the following domains (Guo et al., 2019): attention, working memory (WM), speed of processing, verbal and visual learning memory, and social cognition (Arnsten, Girgis, Gray, & Mailman, 2017; Bowie & Harvey, 2006; Fernandes et al., 2018). WM deficits in schizophrenia are represented by a decreased accuracy and an increased response time on measured tests, which have been observed in various subgroups of schizophrenia (Corcoran et al., 2020; Forbes et al., 2009; Guo et al., 2019), including early-onset (Meshehlom-Gately, Giuliano, Golf, Faraone, & Seidman, 2009; White, Schmidt, & Karatekin, 2010), first-episode (Meshehlom-Gately et al., 2009), and especially chronic schizophrenia patients (Meshehlom-Gately et al., 2009). Though WM deficits are modulated by multiple brain regions, especially the ACC and MPFC (Dash, Moore, Kobori, & Runyan, 2007; Euston, Gruber, & McNaughton, 2012; Stevens et al., 2011), most studies have shown no significant association between WM and glutamate level, while some studies have presented divergent results. This may be due to the different brain regions examined, classifications of schizophrenia, and tools used for cognitive assessment (Reddy-Thooktur et al., 2020). WM has been classed as a crucial part of various test batteries, such as the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) and the repeatable battery for the assessment of neuropsychological status (RBANS) in other studies (Reddy-Thooktur et al., 2020). Most neuroimaging findings suggest that brain regions such as the frontal-parietal network are affected in schizophrenia, which is the neuropathology that may influence WM impairment in schizophrenia patients (Deserno, Sterzer, Wüstenberg, Heinz, & Schlagenhauf, 2012). It has also been proposed that regarding the inverted U-shaped relationship between DLPFC activation and WM performance, in patients with schizophrenia, the relationship is shifted to the right side of the inverted U-shaped curve as compared with healthy controls (HCs) (Callicott et al., 2000; Cools & D’Esposito, 2011; Lenartowicz & McIntosh, 2005; Perlstein, Carter, Noll, & Cohen, 2001). Considering that both the ACC and MPFC are associated with WM in patients with schizophrenia, the glutamatergic distribution and mechanisms in these two closely situated brain regions related to cognition in patients with schizophrenia remain controversial (Reddy-Thooktur et al., 2020; Thomas et al., 2017). We speculated that the relationship between glutamate level and cognitive function could differ between subtypes of schizophrenia; more specifically, between TRS and non-TRS.

To address the effects of glutamatergic neurometabolites on cognitive function in the subgroups of schizophrenia, we hypothesized that the glutamatergic levels in specific brain regions, especially the ACC, differ among TRS, non-TRS, and HC groups, which may lead to differences in cognitive function. The aims of the current study were to (i) reconfirm that glutamatergic levels in TRS patients are higher than those in other subgroups, especially in the ACC; (ii) examine whether TRS and non-TRS patients exhibited poorer performances compared to HCs on the working memory index (WMI) of the WAIS-IV; and (iii) determine
whether the associations between the WMI and glutamatergic levels differed between non-TRS and TRS patients.

**Methods**

**Ethics statement**

This cross-sectional $^1$H-MRS study was conducted at Taichung Veterans General Hospital, Chia Yi Branch, between 2018 and 2020. The study was approved by the ethics committees of a local medical center (IRB nos. A-ER-107-045 and B-ER-107-042), and the protocol was consistent with the principles outlined in an internationally recognized standard for ethical conduct in human research. All participants gave informed consent before enrolment in this study.

**Participants**

This study included participants aged 20–55 years with a diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic Systematic Manual-5th edition. The participants were recruited from outpatient psychiatry clinics and a chronic psychiatric ward in the psychiatry department of Taichung Veterans General Hospital, Chia Yi Branch. Patients who had received no antipsychotic adjustment for at least 6 months prior to recruitment were enrolled in the study. TRS was defined as follows (Howes et al., 2017a): (i) no response to at least two non-clozapine antipsychotic trials, each administered at a dose equivalent to $\geq 600$ mg/day of chlorpromazine (CPZ) for $\geq 6$ weeks; (ii) a Clinical Global Impression-Severity (CGI-S) (Guy, 1976) score $\geq 4$; and (iii) at least two items of the positive symptoms of the PANSS scored $\geq 4$. Patients who did not meet the aforementioned criteria were classified as having non-TRS. The exclusion criteria were as follows: (i) abnormal brain structure disease, (ii) substance-related usage disorder, except nicotine usage, and (iii) severe medical diseases or pregnancy. HCs without psychiatric or organic mental disorders were recruited from the community and provided informed consent.

**Image parameters**

All participants were scanned using a 1.5-T GE Sigma scanner with an eight-channel head coil. MRS was employed to assess the excitatory glutamate–glutamine (Glx) concentration. A three-dimensional T1-weighted inversion recovery magnetic resonance imaging (MRI) scan was performed on all subjects [axial MRI 3D brain volume, echo time (TE) = 2.9 ms, repetition time (TR) = 7.7, inversion time = 450 ms, flip angle = 12°, field of view = 230 mm, matrix size = 256 x 256, and slice thickness = 1.0 mm].

$^1$H-MRS was performed using point-resolved spectroscopy (TE = 35 ms, TR = 2000 ms, spectral width = 2500 Hz, 2048 data points, 128 water-suppressed, 16 water-unsuppressed averages, and eight excitation numbers). The voxels were placed in the bilateral ACC (voxel size = 10.0 mL) and MPFC (voxel size = 10.0 mL), scanned for 9:20 (Ende et al., 2016; Milak et al., 2016). The region and voxel size of the ACC in the current study were similar to the dorsal ACC mentioned in previous articles (Stevens et al., 2011; Tarumi et al., 2020); the MPFC in this study included the partial pregenual ACC in its structure (Stevens et al., 2011). The detailed voxel placement procedures, locations of $^1$H-MRS voxels, and representative spectra are shown in Fig. 1. Spectra were preprocessed using the FID-Appliance (https://github.com/CIC-methods/FID-A), and concentrations of neurometabolites were measured using LC models. Signal-to-noise ratios $\leq 10$, full-width at half-maximum $\geq 10$ Hz, or standard deviation (S.D.) values $\geq 20\%$ were defined as being of poor quality and were excluded from the analyses. In this study, glutamate + glutamine (Glx) was the main neurometabolite outcome. MRS data were fitted and analyzed using LCModel (version 6.3-1K). Data on supplementary neurometabolites, including glutamate, glutamine, myoinositol, glycerophosphocholine + phosphocholine, N-acetylaspartate + N-acetyl aspartylglutamate (NAAx), and creatine + phosphocreatine, were also obtained.

**Clinical assessments**

Clinical assessments included the following: PANSS score (Leucht et al., 2005), CGI-S score, Global Assessment of Functioning symptom severity score, and, specifically to assess WM, the WMI of the WAIS-IV (Benson, Hulac, & Kranzler, 2010).

**Statistical analyses**

The demographic and clinical characteristics of the groups of participants were compared using Fisher’s exact test for dichotomous variables. Differences between groups were tested using one-way...
analysis of variance (ANOVA), with the exception of differences between the non-TRS and TRS groups, for which the t test was used. Post-hoc pairwise comparisons were conducted with Bonferroni corrections for multiple comparisons. Similarly, one-way ANOVA was used to test the hypothesis of group differences in glutamatergic levels. Supplementary analysis of covariance (ANCOVA) was employed to test the robustness of the main finding after controlling some demographic factors, including sex, age, smoking status, educational level, and the use of certain drugs. To test the hypothesis of an association between WM and Glx/NAAx, Pearson correlation was used as the first tool, and Spearman’s correlation analysis was employed for conclusive testing of an association owing to the distribution of the data. The threshold for statistical significance in all analyses was set at $p < 0.05$, with further correction for multiple comparisons when noted (for testing of correlations in the three groups, the control threshold was 0.0167). All statistical analyses were conducted using IBM SPSS Statistics, version 22 (IBM Corporation, Armonk, NY, USA).

**Results**

The demographic and clinical characteristics, including smoking status, of the participants are shown in Table 1. There were no sex differences among the three subgroups. General tendencies toward an older age, a lower educational level, poorer clinical outcomes, and poorer WM were noted among the patient groups, especially the TRS patients. Other results, including scores on the WAIS-IV in domains except WM, and details of the results of treatment with clozapine, clozapine-like agents, first- and second-generation antipsychotics, lithium and mood stabilizers, are presented in online Supplementary Tables S1 and S2. Regarding the concentrations of neurometabolites (Table 2), higher Glx/NAAx in the ACC area was found in the TRS group in comparison with the non-TRS group; this difference remained even after adjustment for covariates (model 1 corrected for age and sex; model 2 corrected for age, sex, smoking status, educational level, and IQ). In addition, we examined whether the difference between the TRS and non-TRS groups remained after controlling for potential confounders, including age, sex, educational level, smoking status, and IQ. The difference remained significant. ANCOVA tables presenting data on neurometabolite levels in the ACC in the TRS and non-TRS patients are presented in online Supplementary Tables S3 and S4. There were no significant differences in neurometabolite levels in the MPFC between groups (as shown in online Supplementary Tables S5 and S6). The group difference in Glx in the ACC remained significant after controlling for the use of several drugs (mood stabilizers: online Supplementary Table S7; antipsychotic agents: online Supplementary Table S8; clozapine and clozapine-like agents: online Supplementary Table S9).

Most clinical and demographic characteristics, including the total PANSS score, were not associated with neurometabolite levels in the groups (Table 3). To test this hypothesis, a series of stratified correlation analyses was conducted. The association between the Glx/NAAx ratio in the ACC and cognitive function (WMI) in the non-TRS patients was significant (Spearman’s $\rho = -0.51$, $p = 0.002$, below the threshold after Bonferroni correction, $p = 0.0167$), while this association was not significant in the TRS patients and HCs (Fig. 2). Similar patterns were found for the Glx/NAAx ratio and WMI.

**Discussion**

The results of our study were in agreement with literature reporting that the ACC glutamatergic level in TRS patients is higher than in non-TRS patients and HCs (Goldstein, Anderson, Pillai, Kydd, & Russell, 2015; Mouchnianitis et al., 2016; Tarumi et al., 2020), similar to the integrated glutamatergic and dopaminergic hypothesis (Huang et al., 2020). In addition to the dopamine hypothesis, the ACC is one of the major areas that modulates positive and negative symptoms and cognitive function, via an underlying mechanism of abnormal distribution of glutamatergic levels with NMDA or $\alpha$-amino-3-hydroxy-5-methyl-4-

---

**Table 1. Demographic data and clinical characteristics of the study participants, stratified into three groups**

| Characteristic                  | Non-TRS ($n = 35$) | TRS ($n = 38$) | Control ($n = 19$) | Test statistics |
|--------------------------------|--------------------|---------------|-------------------|----------------|
| **Gender (male/female)**       | Mean (s.o.)        | Mean (s.o.)   | Mean (s.o.)       | $\chi^2/t/F$   | $p$            | Post-hoc       |
| Male/female                    | 17/18              | 21/17         | 9/10              | 0.47           | 0.80           |                |
| Age (years)                    | 39.77 (8.19)       | 43.58 (8.76)  | 38.05 (8.07)      | 3.28           | 0.04           | TRS > non-TRS > control |
| Smoking status                 | 16/19              | 13/25         | 2/17              | 6.83           | 0.03           | Non-TRS > TRS > control |
| Education (years)              | 12.89 (2.37)       | 11.11 (2.45)  | 17.11 (1.91)      | 42.47          | <0.01          | Control > non-TRS > TRS |
| Duration of illness (years)    | 16.91 (7.56)       | 23.21 (8.37)  | 17.11 (1.91)      | 3.36           | <0.01          |                |
| Dosage (CPZ equivalent)        | 467.91 (186.48)    | 821.36 (181.71) | 381.36 (181.71) | 8.2            | <0.01          |                |
| **Psychiatric ratings: PANSS** |                    |               |                   |                |                |                |
| Total score                    | 38.23 (5.77)       | 83.21 (25.40) | 101.63 (28.51)    | 10.23          | <0.01          |                |
| Positive score                 | 8.20 (1.35)        | 22.11 (6.02)  | 26.67 (6.02)      | 13.35          | <0.01          |                |
| Negative score                 | 7.69 (1.73)        | 17.47 (6.17)  | 20.67 (6.17)      | 9.06           | <0.01          |                |
| General score                  | 18.86 (3.56)       | 37.76 (14.75) | 51.67 (14.75)     | 7.77           | <0.01          |                |
| Aggression score               | 3.40 (0.98)        | 4.87 (3.10)   | 5.67 (3.10)       | 2.68           | <0.01          |                |
| **Cognitive function rating**  |                    |               |                   |                |                |                |
| WMI                            | 84.49 (15.01)      | 74.48 (14.23) | 101.63 (16.13)    | 21.07          | <0.01          | Control > non-TRS > TRS |

TRS, treatment-resistant schizophrenia; CPZ, chlorpromazine; PANSS, positive and negative syndrome scale; WMI, working memory index.
isoaxazolepropionic acid receptor (AMPA) receptor dysfunction (Egerton et al., 2021; Gallinat, McMahon, Kühn, Schubert, & Schaefer, 2016). The phenomenon of neurotoxicity, such as psychotic symptoms caused by ketamine and phencyclidine usage, may also explain the role of the glutamatergic hypothesis in patients with schizophrenia. In contrast, the levels of glutamate neurometabolites were reduced in the MPFC in the schizophrenia patients relative to HC groups, while inconsistent results have been reported in the literature (Smucny et al., 2021). The reason for the non-positive findings in the MPFC is unclear; the glutamatergic concentration, assessed via MRS detection, may be affected by (1) susceptibility artifacts related to the sinus-air effect

| Table 2. Group comparison of the concentrations of neurometabolite covariates in the ACC and MPFC |
|-----------------------------------------------|
| (a) ACC                                       |
|                                               |
| Non-TRS (n = 35)                              |
| Mean (s.d.)                                   |
| TRS (n = 38)                                  |
| Mean (s.d.)                                   |
| Control (n = 19)                              |
| Mean (s.d.)                                   |
| F     | p    | Post-hoc |
|-------|------|----------|
| Glx/NAAx                     1.081 (0.23) | 1.27 (0.39) | 1.13 (0.19) | 4.06 | 0.021 | Non-TRS < TRS |
| Corrected model 1             |
| Glx/NAAx (estimated mean, s.e.) 1.07 (0.04) | 1.29 (0.05) | 1.11 (0.07) | 5.17 | 0.008 | Non-TRS < TRS |
| Corrected model 2             |
| Glx/NAAx (estimated mean, s.e.) 1.06 (0.05) | 1.25 (0.06) | 1.20 (0.10) | 3.60 | 0.032 | Non-TRS < TRS |
| (b) MPFC                         |
| Non-TRS (n = 28)                              |
| Mean (s.d.)                                   |
| TRS (n = 32)                                  |
| Mean (s.d.)                                   |
| Control (n = 15)                              |
| Mean (s.d.)                                   |
| F     | p    | Post-hoc |
|-------|------|----------|
| Glx/NAAx                     1.49 (0.36) | 1.59 (0.79) | 1.44 (0.37) | 0.38 | 0.69  |
| Corrected model 1             |
| Glx/NAAx (estimated mean, s.e.) 1.50 (0.11) | 1.58 (0.11) | 1.46 (0.15) | 0.21 | 0.81  |
| Corrected model 2             |
| Glx/NAAx (estimated mean, s.e.) 1.51 (0.11) | 1.60 (0.14) | 1.41 (0.23) | 0.19 | 0.82  |

ACC, anterior cingulate cortex; MPFC, medial prefrontal cortex; TRS, treatment-resistant schizophrenia; Glx, total glutamate + glutamine; NAAx, N-acetylaspartate + N-acetyl aspartylglutamate; s.e., standard error; FSIQ, full-scale IQ.
Corrected model 1: adjusted for age and sex; pairwise comparison with Bonferroni correction.
Corrected model 2: adjusted for age, sex, smoking status, educational level, and FSIQ; pairwise comparison with Bonferroni correction.

| Table 3. Associations between demographic characteristics and the glutamatergic level in the ACC in the three groups |
|---------------------------------------------------------------|
| Non-TRS (n = 35)                              | TRS (n = 38) | Control (n = 19) |
| Statistics | p   | Statistics | p   | Statistics | p   |
| Sex         |
| Glx/NAAx    0.75 | 0.46 | 1.50 | 0.14 | 0.14 | 0.89 |
| Glu/NAAx    0.23 | 0.82 | 1.77 | 0.08 | 0.39 | 0.70 |
| Age         |
| Glx/NAAx    −0.13 | 0.46 | −0.24 | 0.15 | 0.37 | 0.12 |
| Glu/NAAx    −0.35 | 0.04* | −0.11 | 0.52 | 0.23 | 0.33 |
| Educational level |
| Glx/NAAx    −0.36 | 0.84 | −0.27 | 0.11 | −0.09 | 0.73 |
| Glu/NAAx    0.15 | 0.41 | −0.23 | 0.17 | −0.18 | 0.06 |
| WMI          |
| Glx/NAAx    −0.42 | 0.01* | −0.2  | 0.23 | 0.07 | 0.78 |
| Glu/NAAx    −0.23 | 0.19 | −0.15 | 0.38 | 0.36 | 0.14 |
| PANSS        |
| Glx/NAAx    −0.26 | 0.14 | 0.12 | 0.48 | NA  |
| Glu/NAAx    −0.16 | 0.54 | 0.09 | 0.61 | NA  |

TRS, treatment-resistant schizophrenia; ACC, anterior cingulate cortex; Glu, glutamate; Glx, total glutamate + glutamine; NAAx, N-acetylaspartate + N-acetyl aspartylglutamate; WMI, working memory index; PANSS, positive and negative syndrome scale.

Note: The statistics shown are from the t test for sex, while Pearson’s R was used for the other demographic characteristics.

*p < 0.05.
ACC, anterior cingulate cortex. NAAx, or HCs. TRS, treatment-resistant schizophrenia; Glx, total glutamate + glutamine; age and a lower educational level (Chai et al., 2018; Kondo et al., 2011) particularly with regards to WM, owing to tendencies toward an older cognitive function in patient groups, especially TRS groups, particularly in the subgroups (McCutcheon et al., 2020; Thomas et al., 2017). The ACC, as a part of the limbic system, modulates not only emotion, but also attention, which plays a pivotal role in WM impairment and improvement before and after medical treatment (Arnst en et al., 2017; Tanaka, 2006). The ACC mediates the linkage between the parietal lobe and the prefrontal cortex for central executive function (Chai, Abd Hamid, & Abdullah, 2018; Deserno et al., 2012; Kondo et al., 2004). The significant difference in the relationship of WM with the ACC glutamatergic level between the TRS and non-TRS patients in our study was in agreement with similar studies (Reddy-Thoottkur et al., 2020); however, empirical studies of the correlation between WM and glutamatergic level in TRS and non-TRS patients are scarce.

Studies of HCs and patient groups have reported poorer cognitive function in patient groups, especially TRS groups, particularly with regards to WM, owing to tendencies toward an older age and a lower educational level (Chai et al., 2018; Kondo et al., 2004). In the current study, we confirmed that WM was related to the glutamatergic level in the ACC in the patients with non-TRS. This finding was similar to previous evidence indicating that acute or chronic stress affects intra- and extracellular glutamatergic concentrations in animal models (Yuen, Wei, & Yan, 2017) and the dopamine–WM relationship in humans (Cools & D’Esposito, 2011). An inverted U-shaped relationship was identified for the association between WM and connectivity of the dorsolateral prefrontal cortex (Callicott et al., 2000; Cools & D’Esposito, 2011; Lenartowicz & McIntosh, 2005; Perlstein et al., 2001), and we speculated that the same mechanisms could exist in the ACC. However, no associations were found between WM and glutamatergic levels in the HC and TRS groups in previous studies. Whether this inverted U-shaped relationship exists between glutamate and WM is unclear. Another potential model is an upside-down exponential function with concave down decreasing. For healthy subjects on the left-hand side of the curve, the glutamate level is normal, and does not harm WM, while for patients with non-TRS, the glutamate level tends toward being over the normal range, and WM function is affected in the pattern of a negative association. In patients with TRS, glutamate levels are extremely high, and WM is severely damaged. The association between glutamate and WM is weak.

We had proposed that (Huang et al., 2020) patients with TRS with a long-term full dopaminergic antagonist prognosis were characterized by a higher glutamatergic concentration in the brain. In this case, without efficacious treatment to relieve chronic stress, cognitive decline may be irreversible. Considering the hypothesis of glutamate in TRS and non-TRS, glutamatergic modulators such as sodium benzoate, sarcosine, or lamotrigine may represent new promising treatments to improve cognitive function in patients with schizophrenia, TRS, or other severe psychiatric disorders (Chang, Lin, Liu, Chen, & Lane, 2020; Lin et al., 2020a, 2020b). Moreover, the results are diverse based on different brain regions, age distributions, schizophrenia subgroups, and cognition measurements. In conclusion, cognitive dysfunction in different brain areas and classification of schizophrenia based on the glutamatergic hypothesis remain unclear, and are still plausible. Further research and studies are required for further investigation to inform future clinical practice.

The current study had several potential strengths. It is important to note that the TRS and non-TRS patients in the study were admitted to the chronic ward or half-way house of the same hospital, and were subject to the same food supplements, rehabilitation programs, and drug-monitoring systems. In addition, we employed the latest data in the analysis that indicated correlations between WMI and glutamatergic neumonometabolites in the TRS patients, while no associations were observed in the non-TRS and HC groups.

We acknowledge some limitations of this study, which may have led to the unexplained results and are worthy of mention. The first was that the equipment used for MRI scanning at 1.5-Tesla disturbed detection of the signals of glutamate, which did not have adequate resolution to measure the signal of glutamine clearly. Therefore, we attempted to obtain the glutamatergic concentration ratio to NAAx rather than the pure glutamate concentration, as has been employed for analysis in some studies (Reddy-Thoottkur et al., 2020). Second, we selected a higher dosage of antipsychotics (equivalent to more than 600 mg CPZ) to indicate TRS; hence, the TRS participants were classified based on a high clozapine dosage, and those on a low clozapine dosage were classified as non-TRS patients. The cognitive function of the participants in this study was measured using the WAIS-IV IQ, which is not commonly used for the evaluation of cognition in...
The drugs used in the two groups differed greatly. Although our findings remained robust after controlling for certain drugs (see online Supplementary Tables S7–S9), this should be validated in a further experimental study, in which drug use in the two groups was matched. Finally, the sample size of the HC group was small as compared with groups in other published studies on schizophrenia.

In summary, we found a higher ACC glutamatergic concentration in the TRS patients than that in the other two groups, and the glutamatergic neurometabolite levels in the ACC of the non-TRS patients were negatively associated with WM and were independent of covariates such as age and sex. Based on the glutamatergic hypothesis previously reported, an elevated glutamatergic distribution leads to increases in psychotic symptoms and decreases in cognitive function based on NMDA receptor or AMPA receptor dysfunction. In clinical practice and research, some glutamatergic modulators, such as sodium benzoate, valproic acid, lamotrigine, and sarcosine, have been efficacious in the treatment of schizophrenia and other psychiatric disorders (Li et al., 2019; Lin et al., 2020a, 2020b). Although the underlying mechanisms of the glutamatergic concentration in different cognitive function subgroups in TRS and non-TRS patients are still unknown, the glutamatergic concentration as estimated by MRS may be a personalized predictive biomarker or treatment response detector for patients with schizophrenia.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S003329172100533X

Acknowledgements. This study was supported by Taichung Veterans General Hospital, Foundation Chia-Yi Branch Hospital Research Program (R-VHCY108001 and R-VHCY108003). The authors thank Mr. Chien Ting Lin for his administrative support.

Financial support. This study was supported by Taichung Veterans General Hospital, Foundation Chia-Yi Branch Hospital Research Program (R-VHCY108001 and R-VHCY108003).

Conflict of interest. The funding institutions of this study had no further role in the study design, the collection, analysis and interpretation of data, the writing of this paper, or the decision to submit for publication. The authors report no financial relationships with commercial interests.

References

Arnsten, A. F., Girgis, R. R., Gray, D. L., & Mailman, R. B. (2017). Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biological Psychiatry, 81, 67–77.

Benson, N., Hulac, D. M., & Kranzer, J. H. (2010). Independent examination of the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV): What does the WAIS-IV measure? Psychological Assessment, 22, 121.

Borisova, T., Kucherenko, D., Soldatkin, O., Kucherenko, I., Pastukhov, A., Nazarova, A., ... Soldatkin, A. (2018). An amperometric glutamate biosensor for monitoring glutamate release from brain nerve terminals and in blood plasma. Analytica Chimica Acta, 1022, 113–123.

Bowie, C. R., & Harvey, P. D. (2006). Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatric Disease and Treatment, 2, 531.

Callicott, J. H., Bertolino, A., Mattay, V. S., Langheim, F. J., Duyn, J., Coppola, R., ... Weinerberger, D. R. (2000). Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cerebral Cortex, 10, 1078–1092.

Chai, W. J., Abd Hamid, A. I., & Abdullah, J. M. (2018). Working memory from the psychological and neurosciences perspectives: A review. Frontiers in Psychology, 9, 401.

Chang, C.-H., Lin, C.-H., Liu, C.-Y., Chen, S.-J., & Lane, H.-Y. (2020). Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 34, 495–505.

Charlson, F. J., Ferrari, A. J., Santomarco, D. F., Diminic, S., Stockings, E., Scott, J. G., ... Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophrenia Bulletin, 44, 1195–1203.

Conus, P., Seidman, L. J., Fourrier, M., Xin, L., Cleusix, M., Baumann, P. S., ... Gholam-Rezaee, M. (2018). N-acetylcytistene in a double-blind randomized placebo-controlled trial: Toward biomarker-guided treatment in early psychosis. Schizophrenia Bulletin, 44, 317–327.

Cools, R., & D’Esposito, M. (2011). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biological Psychiatry, 69, e113–e125.

Corcoran, M., Hawkins, E. L., O’Hara, D., Whalley, H. C., Hall, J., Lawrie, S. M., & Dauvermann, M. R. (2020). Are working memory and glutamate concentrations involved in early-life stress and severity of psychosis? Brain and Behavior, 10, e01616.

Dash, P. K., Moore, A. N., Kobori, N., & Runyan, J. D. (2007). Molecular activity underlying working memory. Learning and Memory, 14, 554–563.

de la Fuente-Sandoval, C., Reyes-Madrigal, F., Mao, X., León-Ortiz, P., Rodríguez-Mayoral, O., Jung-Cook, H., ... Shungu, D. C. (2018). Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients. Biological Psychiatry, 83, 475–483.

Deserno, L., Sterzer, P., Wüstenberg, T., Heinz, A., & Schlagenhauf, F. (2012). Reduced prefrontal-parietal effective connectivity and working memory deficits in schizophrenia. Journal of Neuroscience, 32, 12–20.

Egerton, A., Murphy, A., Donocik, J., Anton, A., Barker, G. J., Collier, T., ... Emsley, R. (2021). Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: A multicenter position emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophrenia Bulletin, 47, 505–516.

Ende, G., Cackowski, S., Van Eijk, J., Sack, M., Demirakca, T., Kleindienst, N., ... Schmahl, C. (2016). Impulsivity and aggression in female BPD and ADHD patients: Association with ACC glutamate and GABA concentrations. Neuropsychopharmacology, 41, 410–418.

Euston, D. R., Gruber, A. J., & McNaughton, B. L. (2012). The role of medial prefrontal cortex in memory and decision making. Neuron, 76, 1057–1070.

Fernandes, J. M., Cajio, R., Lopes, R., Jerónimo, R., & Barahona-Correia, J. B. (2018). Social cognition in schizophrenia and autism spectrum disorders: A systematic review and meta-analysis of direct comparisons. Frontiers in Psychiatry, 9, 504.

Forbes, N., Carrick, L., McIntosh, A., & Lawrie, S. (2009). Working memory in schizophrenia: A meta-analysis. Psychological Medicine, 39, 889.

Frodl, T., Meisenzahl, E. M., Zetzsche, T., Born, C., Groll, C., Jäger, M., ... Möller, H.-J. (2002). Hippocampal changes in patients with a first episode of major depression. American Journal of Psychiatry, 159, 1112–1118.

Gallinat, J., McMahon, K., Kühn, S., Schubert, F., & Schaefer, M. (2016). Cross-sectional study of glutamate in the anterior cingulate and hippocampus in schizophrenia. Schizophrenia Bulletin, 42, 425–433.
Goldstein, M. E., Anderson, V. M., Pillai, A., Kydd, R. R., & Russell, B. R. (2015). Glutamatergic neurometabolites in clozapine-responsive and resistant schizophrenia. International Journal of Neuropsychopharmacology, 18, pyu117.

Guo, J., Ragland, J. D., & Carter, C. S. (2019). Memory and cognition in schizophrenia. Molecular Psychiatry, 24, 633–642.

Guy, W. (1976). ECDU Assessment manual for psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.

Howes, O., McCutcheon, R., & Stone, J. (2015). Glutamate and dopamine in schizophrenia: An update for the 21st century. Journal of Psychopharmacology, 29, 97–115.

Howes, O. D., McCutcheon, R., Agid, O., De Bartolomeis, A., Van Beveren, N. J., Birnbaum, M. L., ... Carpenter, W. T. (2017a). Treatment-resistant schizophrenia: Treatment response and resistance in psychosis (TTRIP) working group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry, 174, 216–229.

Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2017b). The role of genes, stress, and dopamine in the development of schizophrenia. Biological Psychiatry, 81, 9–20.

Huang, L.-C., Lin, S.-H., Tseng, H.-H., Chen, K. C., & Yang, Y. K. (2020). The integrated model of glutamate and dopamine hypothesis for schizophrenia: Prediction and personalized medicine for prevent potential treatment-resistant patients. Medical Hypotheses, 143, 110159.

Hutcheson, N. L., Reid, M. A., White, D. M., Kruguljac, N. V., Avsar, K. B., Bolding, M. S., ... Lahti, A. C. (2012). Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophrenia Research, 140, 136–142.

Kondo, H., Morishita, M., Osaka, N., Osaka, M., Fukuyama, H., & Shibasaki, H. (2004). Functional roles of the cingulo-frontal network in performance on working memory. NeuroImage, 21, 2–14.

Kruguljac, N. V., Carle, M., Frolíck, M. A., Tran, S., Yassa, M. A., White, D. M., ... Lahti, A. C. (2018). Mnemonic discrimination deficits in first-episode psychosis and a ketamine model suggests dentate gyrus pathology linked to N-methyl D-aspartate receptor hypofunction. Biological Psychiatry, 3, 231–238.

Lenartowicz, A., & McIntosh, A. R. (2005). The role of anterior cingulate cortex in working memory is shaped by functional connectivity. Journal of Cognitive Neuroscience, 17, 1026–1042.

Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. G. (2005). What does the PANSS mean? Schizophrenia Research, 79, 231–238.

Li, C.-T., Yang, K.-C., & Lin, W.-C. (2020). Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: Evidence from clinical neuroimaging studies. Frontiers in Psychiatry, 9, 767.

Lin, C.-H., Chen, Y.-M., & Lane, H.-Y. (2020a). Novel treatment for the most resistant schizophrenia: Dual activation of NMDA receptor and antioxidant. Current Drug Targets, 21, 610–615.

Lin, C.-H., Hashimoto, K., & Lane, H.-Y. (2019a). Glutamate-related biomarkers for neuropsychiatric disorders. Frontiers in Psychiatry, 10, 904.

Lin, C.-H., & Lane, H.-Y. (2019). Early identification and intervention of schizophrenia: Insight from hypotheses of glutamate dysfunction and oxidative stress. Frontiers in Psychiatry, 10, 93.

Lin, C.-H., Yang, H.-T., Chen, P.-K., Wang, S.-H., & Lane, H.-Y. (2020b). Precision medicine of sodium benzoate for the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD). Neuropsychiatric Disease and Treatment, 16, 509.

Lin, C.-H., Yang, H.-T., & Lane, H.-Y. (2019b). D-Glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer’s disease or mild cognitive impairment. Pharmacology Biochemistry and Behavior, 185, 172760.

Luering, R., Weigand, T., Bogdahn, U., & Schmidt-Wilcke, T. (2008). Working memory performance is correlated with local brain morphology in the medial frontal and anterior cingulate cortex in fibromyalgia patients: Structural correlates of pain–cognition interaction. Brain, 131, 3222–3231.